• NAGULA NANDINI
• SUSHMA DESAI
• CHANDRASEKHARA RAO BARU

Cisplatin is an alkylating agent and an anticancer medication. The main objectives of this work were to prepare the Cisplatin Liposomes and assess their effectiveness. By creating pegylated liposomes, this formulation can lessen adverse effects and pinpoint the location of action with the stabilizer's effect on drug entrapment efficiency. Hydrogenated soy phosphatidyl choline and cholesterol, which are less hazardous, were used to create this liposomal formulation. The medication, carrier, ammonium sulphate, and stabilizer were combined in a rotary evaporator to create the liposomes using the dried thin film hydration process. The temperature, vacuum, and RPM were all kept constant in line with this. Following processing, the liposomes were frozen and sent for additional analysis. The physical in addition chemical properties of the generated Liposomes from the formulations F1, F2, F3, F4, and F6 were examined, including their average size, shape, and zeta potential. The tested batches showed good physicochemical properties in the F6 formulation. The produced liposomes of F1 through F6 were assessed for assay and percentage of free drug. In comparison to other formulations, the F6 formulation had the highest percentage of free medicine. Diffusion studies using this newly developed liposomal drug delivery system in phosphate buffer pH7.4 were also examined. using the membrane diffusion method. Comparing the F6 formulation to other formulations, it was discovered that the drug's release was somewhat sustained. F6 Formulation's release kinetics were refined. The F6 formulation adheres to Case II transport when used with the Korsmeyer model for the drug release mechanism. The kinetic results of the F6 formulation are recovering than those of other formulations. The Cisplatin's long-term stability Liposomes was examined for 60 days at room temperature and 4°C. The storage was used to determine the assay for the samples at different intervals. It was discovered that the liposomes kept at 4 °C were stable for two months. When related to the regular medication and neutral Liposomes, the results of physical characterization, in-vitro evaluation, release kinetics, and stability investigations suggested that Cisplatin-containing negative charged Liposomes might be used to treat ovarian and testicular cancer.

Formulation, Evaluation, Lyophilization, Cisplatin, Liposomes

"FORMULATION, EVALUATION AND LYOPHILIZATION OF CISPLATIN LOADED LIPOSOMES", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 10, page no.c770-c780, October-2025, Available :http://www.jetir.org/papers/JETIR2510297.pdf

"FORMULATION, EVALUATION AND LYOPHILIZATION OF CISPLATIN LOADED LIPOSOMES", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 10, page no. ppc770-c780, October-2025, Available at : http://www.jetir.org/papers/JETIR2510297.pdf